218 related items for PubMed ID: 10931407
1. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.
J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
[Abstract] [Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
3. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
4. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D.
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[Abstract] [Full Text] [Related]
5. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[Abstract] [Full Text] [Related]
6. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
[Abstract] [Full Text] [Related]
7. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov 27; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
8. [Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease].
Du ZD, Di Z, Du JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF.
Zhonghua Yi Xue Za Zhi; 2009 Jul 14; 89(26):1841-3. PubMed ID: 19953930
[Abstract] [Full Text] [Related]
9. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.
Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J.
Eur J Pediatr; 2007 Feb 14; 166(2):131-7. PubMed ID: 16896641
[Abstract] [Full Text] [Related]
10. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease].
Peng Q, Wu Q, Chen CH, Hong H, Zhang LY.
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun 14; 8(3):208-10. PubMed ID: 16787593
[Abstract] [Full Text] [Related]
11. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S, Brandi ML, Falcini F.
J Rheumatol; 2005 Nov 14; 32(11):2233-8. PubMed ID: 16265708
[Abstract] [Full Text] [Related]
12. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
Int J Rheum Dis; 2013 Apr 14; 16(2):168-72. PubMed ID: 23773640
[Abstract] [Full Text] [Related]
13. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M.
J Allergy Clin Immunol; 2008 Nov 14; 122(5):1008-1013.e8. PubMed ID: 18930517
[Abstract] [Full Text] [Related]
14. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT.
J Trop Pediatr; 2005 Apr 14; 51(2):98-101. PubMed ID: 15677370
[Abstract] [Full Text] [Related]
15. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S, Safari M, Amin R.
Kaohsiung J Med Sci; 2005 Sep 14; 21(9):401-4. PubMed ID: 16248123
[Abstract] [Full Text] [Related]
16. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T.
J Pediatr; 2006 Aug 14; 149(2):237-40. PubMed ID: 16887442
[Abstract] [Full Text] [Related]
17. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ, Kim KH, Chun JK, Kim DS.
Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
[Abstract] [Full Text] [Related]
18. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
Pediatr Allergy Immunol; 2010 May 31; 21(3):515-21. PubMed ID: 20546528
[Abstract] [Full Text] [Related]
19. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb 31; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
20. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission.
Nomura Y, Arata M, Koriyama C, Masuda K, Morita Y, Hazeki D, Ueno K, Eguchi T, Kawano Y.
J Pediatr; 2010 May 31; 156(5):786-91. PubMed ID: 20097355
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
